Skip to main content

Table 3 Influence of anxiety on RA disease activity, pain and fatigue over 12 months

From: Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial

   Crude Adjusteda
β (95%CI) p value β (95%CI) p value
Average scores (0, 6 and 12 months)
DAS28-ESR None Reference   Reference  
Moderate 0.19 (−0.04, 0.42) 0.097 0.14 (−0.15, 0.42) 0.340
Severe 0.34 (0.11, 0.57) 0.003 0.32 (−0.03, 0.66) 0.071
Pain None Reference   Reference  
Moderate 9.05 (4.01, 14.09) <0.001 3.44 (−2.76, 9.63) 0.277
Severe 15.03 (9.60, 20.47) <0.001 9.60 (2.30, 16.90) 0.010
Fatigue None Reference   Reference  
Moderate 15.15 (9.62, 20.68) <0.001 0.22 (−6.56, 7.00) 0.949
Severe 21.42 (15.08, 27.76) <0.001 3.12 (−4.39, 10.62) 0.415
12-month outcomes
   Crude
Odds ratio (95%CI)
p value Adjusteda
Odds ratio (95%CI)
p value
Remission DAS28-ESR (<2.6) None Reference   Reference  
Moderate 0.74 (0.29, 1.89) 0.528 0.72 (0.25, 2.10) 0.549
Severe 0.79 (0.28, 2.20) 0.647 0.98 (0.33, 2.92) 0.968
Change in pain (≥10 units) None Reference   Reference  
Moderate 0.51 (0.22, 1.16) 0.110 0.46 (0.19, 1.11) 0.083
Severe 2.43 (0.96, 6.16) 0.061 2.88 (0.98, 7.94) 0.046
Change in fatigue (≥10 units) None Reference   Reference  
Moderate 1.11 (0.51, 2.40) 0.790 1.12 (0.48, 2.62) 0.785
Severe 0.99 (0.41, 2.38) 0.985 1.41 (0.54, 3.69) 0.488
  1. aAdjustment for age, gender, ethnicity, disease duration, NHS region and trial arm; anxiety: none n=183; moderate n=65; severe n=50